BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 10080598)

  • 1. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma.
    Foran JM; Rohatiner AZ; Coiffier B; Barbui T; Johnson SA; Hiddemann W; Radford JA; Norton AJ; Tollerfield SM; Wilson MP; Lister TA
    J Clin Oncol; 1999 Feb; 17(2):546-53. PubMed ID: 10080598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas.
    Decaudin D; Bosq J; Tertian G; Nedellec G; Bennaceur A; Venuat AM; Bayle C; Carde P; Bendahmane B; Hayat M; Munck JN
    J Clin Oncol; 1998 Feb; 16(2):579-83. PubMed ID: 9469344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.
    Hagenbeek A; Eghbali H; Monfardini S; Vitolo U; Hoskin PJ; de Wolf-Peeters C; MacLennan K; Staab-Renner E; Kalmus J; Schott A; Teodorovic I; Negrouk A; van Glabbeke M; Marcus R
    J Clin Oncol; 2006 Apr; 24(10):1590-6. PubMed ID: 16575010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fludarabine phosphate in chronic lymphoproliferative diseases. The French Group on CLL.
    Binet JL
    Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):5-7. PubMed ID: 7685518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New initiatives with fludarabine monophosphate in hematologic malignancies.
    Keating MJ; O'Brien S; Robertson LE; Kantarjian H; Dimopoulos M; McLaughlin P; Cabanillas F; Gregoire V; Yang LY; Gandhi V
    Semin Oncol; 1993 Oct; 20(5 Suppl 7):13-20. PubMed ID: 7694371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.
    Foran JM; Oscier D; Orchard J; Johnson SA; Tighe M; Cullen MH; de Takats PG; Kraus C; Klein M; Lister TA
    J Clin Oncol; 1999 May; 17(5):1574-9. PubMed ID: 10334546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Solal-Céligny P; Brice P; Brousse N; Caspard H; Bastion Y; Haïoun C; Bosly A; Tilly H; Bordessoule D; Sebban C; Harousseau JL; Morel P; Dupas B; Plassart F; Vasile N; Fort N; Leporrier M
    J Clin Oncol; 1996 Feb; 14(2):514-9. PubMed ID: 8636765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.
    Redman JR; Cabanillas F; Velasquez WS; McLaughlin P; Hagemeister FB; Swan F; Rodriguez MA; Plunkett WK; Keating MJ
    J Clin Oncol; 1992 May; 10(5):790-4. PubMed ID: 1373760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine phosphate therapy of non-Hodgkin's lymphoma.
    Hochster H; Cassileth P
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):63-5. PubMed ID: 1699284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.
    Rossi JF; van Hoof A; de Boeck K; Johnson SA; Bron D; Foussard C; Lister TA; Berthou C; Kramer MH; Littlewood TJ; Marcus RE; Deconinck E; Montillo M; Guibon O; Tollerfield SM
    J Clin Oncol; 2004 Apr; 22(7):1260-7. PubMed ID: 15051774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report.
    Sorensen JM; Vena DA; Fallavollita A; Chun HG; Cheson BD
    J Clin Oncol; 1997 Feb; 15(2):458-65. PubMed ID: 9053466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine phosphate in lymphoma: an important new therapeutic agent.
    McLaughlin P; Robertson LE; Keating MJ
    Cancer Treat Res; 1996; 85():3-14. PubMed ID: 9043771
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
    Morris GJ; Millenson MM; Padavic-Shaller K; Wang H; Rogatko A; Clyde J; Boyd RL; Yeslow G; Halbherr T; Schilder RJ; Smith MR
    Haematologica; 2004 Dec; 89(12):1484-91. PubMed ID: 15590399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma.
    Tobinai K; Watanabe T; Ogura M; Morishima Y; Ogawa Y; Ishizawa K; Minami H; Utsunomiya A; Taniwaki M; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Hayashi M; Seriu T; Hotta T
    J Clin Oncol; 2006 Jan; 24(1):174-80. PubMed ID: 16330664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia.
    Boogaerts MA; Van Hoof A; Catovsky D; Kovacs M; Montillo M; Zinzani PL; Binet JL; Feremans W; Marcus R; Bosch F; Verhoef G; Klein M
    J Clin Oncol; 2001 Nov; 19(22):4252-8. PubMed ID: 11709569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
    Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia.
    Del Giudice I; Matutes E; Osuji N; Parry-Jones N; Swansbury J; Catovsky D
    Haematologica; 2005 Feb; 90(2):268-70. PubMed ID: 15710588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
    Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.
    Keating MJ; Kantarjian H; O'Brien S; Koller C; Talpaz M; Schachner J; Childs CC; Freireich EJ; McCredie KB
    J Clin Oncol; 1991 Jan; 9(1):44-9. PubMed ID: 1702145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma].
    Arima N; Mizoguchi H; Shirakawa S; Tomonaga M; Takatsuki K; Ohno R
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):619-29. PubMed ID: 10234292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.